REN Sheng-xiang. Second-Line Therapy for Advanced NSCLC Patients With Negative Oncogenic Driver Mutation: Chemotherapy Remain on the Board[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 19-20. DOI: 10.12019/j.issn.1671-5144.202502001
|
Citation:
|
REN Sheng-xiang. Second-Line Therapy for Advanced NSCLC Patients With Negative Oncogenic Driver Mutation: Chemotherapy Remain on the Board[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 19-20. DOI: 10.12019/j.issn.1671-5144.202502001
|
REN Sheng-xiang. Second-Line Therapy for Advanced NSCLC Patients With Negative Oncogenic Driver Mutation: Chemotherapy Remain on the Board[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 19-20. DOI: 10.12019/j.issn.1671-5144.202502001
|
Citation:
|
REN Sheng-xiang. Second-Line Therapy for Advanced NSCLC Patients With Negative Oncogenic Driver Mutation: Chemotherapy Remain on the Board[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 19-20. DOI: 10.12019/j.issn.1671-5144.202502001
|
DownLoad: